S
Shelmer D. Blackburn
Researcher at University of California, San Diego
Publications - 6
Citations - 4732
Shelmer D. Blackburn is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Pulmonary hypertension & Hemodynamics. The author has an hindex of 6, co-authored 6 publications receiving 4554 citations. Previous affiliations of Shelmer D. Blackburn include GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Robyn J. Barst,Lewis J. Rubin,Walker Long,Michael D. McGoon,Stuart Rich,David B. Badesch,Bertron M. Groves,Victor F. Tapson,Robert C. Bourge,Bruce H. Brundage,Spencer K. Koerner,David Langleben,Cesar A. Keller,Srinivas Murali,Barry F. Uretsky,Linda M. Clayton,Maria M. Jöbsis,Shelmer D. Blackburn,Denise Shortino,James W. Crow +19 more
TL;DR: As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.
Journal ArticleDOI
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
Gérald Simonneau,Robyn J. Barst,Nazzareno Galiè,Robert Naeije,Stuart Rich,Robert C. Bourge,Anne Keogh,Ronald J. Oudiz,Adaani E. Frost,Shelmer D. Blackburn,James W. Crow,Lewis J. Rubin +11 more
TL;DR: Chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension and significantly improved indices of dyspnea, signs and symptoms of pulmonary hypertension, and hemodynamics.
Journal ArticleDOI
Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension
Alan L. Hinderliter,Park W. Willis,Robyn J. Barst,Stuart Rich,Lewis J. Rubin,David B. Badesch,Berton M. Groves,Michael D. McGoon,Victor F. Tapson,Robert C. Bourge,Bruce H. Brundage,Spencer K. Koerner,David Langleben,Cesar A. Keller,Srinivas Murali,Barry F. Uretsky,Gary G. Koch,Shu Li,Linda M. Clayton,Maria M. Jöbsis,Shelmer D. Blackburn,James W. Crow,Walker Long +22 more
TL;DR: The echocardiographic characteristics of participants in this trial; the relationships of echOCardiographic variables to hemodynamic parameters, exercise capacity, and quality of life; and the echoprostenol changes associated with prostacyclin therapy are described.
Journal Article
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension
Alan L. Hinderliter,Park W. Willis,Robyn J. Barst,Stuart Rich,Lewis J. Rubin,David B. Badesch,Berton M. Groves,Michael D. McGoon,Victor F. Tapson,Robert C. Bourge,Bruce H. Brundage,Spencer K. Koerner,David Langleben,Cesar A. Keller,Srinivas Murali,Barry F. Uretsky,Gary G. Koch,Shu Li,Linda M. Clayton,Maria M. Jöbsis,Shelmer D. Blackburn,James W. Crow,Walker Long +22 more
TL;DR: In a recent prospective randomized study of severely symptomatic patients, treatment with prostacyclin (epoprostenol) produced improvements in hemodynamics, quality of life, and survival as mentioned in this paper.
Journal ArticleDOI
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension.
Vallerie V. McLaughlin,Sean Gaine,Sean Gaine,Robyn J. Barst,Ronald J. Oudiz,Robert C. Bourge,Adaani E. Frost,Ivan M. Robbins,Victor F. Tapson,Michael D. McGoon,David B. Badesch,Jeff Sigman,Robert Roscigno,Shelmer D. Blackburn,Carl Arneson,Lewis J. Rubin,Stuart Rich +16 more
TL;DR: Subcutaneous treprostinil has favorable hemodynamic effects when given acutely and in the short term and can be given safely to an ambulatory patient with a novel subcutaneous delivery pump system.